BridgeBio Pharma, Inc. Common Stock
BBIO Real Time Price USDRecent trades of BBIO by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in BBIO holdings by institutional investors
Quarterly net insider trading by BBIO's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$500,000 Jul 20, 2026 Issue: Pharmacy
-
$280,000 Jul 17, 2026 Issue: Pharmacy
-
$420,000 Apr 20, 2026 Issue: Pharmacy
-
$270,000 Oct 20, 2025 Issue: Pharmacy
-
$320,000 Jul 17, 2025 Issue: Pharmacy
-
$320,000 Apr 18, 2025 Issue: Pharmacy
-
$320,000 Jan 20, 2025 Issue: Pharmacy
-
$170,000 Oct 18, 2024 Issue: Pharmacy
-
$170,000 Jul 19, 2024 Issue: Pharmacy
-
$120,000 Jan 12, 2024 Issue: Pharmacy
Former government officials who have lobbied for BBIO
17 former government officials from 13 congressional offices at 5 lobbying firms have lobbied for BBIO, most recently Jul 20, 2026.
-
Scott Hinkle House New Sr. Leg. Assistant and Counsel, Policy Dir. and Counsel, Leg. Dir. and Counsel, Deputy Chief of Staff (CoS)/Leg. Dir./Counsel, CoS and Counsel, DC CoS and Counsel, Sr. Advisor and Counsel for Rep. Juan Vargas; CoS and Counsel for Rep. Raul Ruiz -
Jeff Mackinnon House LD & LA Rep. Joe Barton (RTexas) -
Jeffery Mortier House Prof Staff on E&C Cmte, LA Rep Whitfield and Intern Devin Nunes -
Sarah Walter Senate Former Legislative Director/Chief Counsel, Sen. John Breaux -
Edward Whitfield House U.S. Representative (21 yrs.)
-
Kristen Bautz House Senior Advisor and Special Projects Coordinator, Rep Wasserman Shultz
-
Dylan Moore House Intern/Staff Assistant, Speaker John Boehner (OH-8); Legislative Assistant/Legislative Director/Deputy Chief of Staff, Rep. Larry Bucshon (IN-8); Intern, Rep. Mike Turner (OH-10) -
Constantine Hingson Senate Chief of Staff, Senator Dan Coats; Counsel/Legislative Director, Senator Judd Gregg; General Counsel, Senator Elizabeth Dole
BBIO Estimated quarterly lobbying spending
BBIO Revenue by Segment or Geography
New BBIO patent grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded to BBIO from public contracts
Recent insights relating to BBIO
Recent picks made for BBIO stock on CNBC
ETFs with the largest estimated holdings in BBIO
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $BBIO stock a Buy, Sell, or Hold?
- What is the price target for $BBIO stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $BBIO stock?
- Who owns the most shares of $BBIO stock?
- What funds own $BBIO stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BBIO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
- Address Palo Alto, CA
- Market Cap 13.0 billion
- Employees 839
- Industrial Classification Pharmaceutical Preparations
We estimate that -- received a compensation of -- in --, making them the highest paid executive at BBIO, per a recent SEC DEF 14A filing. We estimate that the median employee at BridgeBio Pharma, Inc. is paid $348,914.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|